Gene · 1289
COL5A1: collagen type V alpha 1 chain
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. COL5A1: collagen type V alpha 1 chain. Genes, record 1289. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1289
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P20908 | Collagen alpha-1(V) chain | 1,838 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents98
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4705273 A2 | 2026-03-11 | 499 | P20908 | Espacenet |
| EP 4694927 A1 | 2026-02-18 | 28 | P20908 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9014 | P20908 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9261 | P20908 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 3315 | P20908 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5958 | P20908 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5958 | P20908 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9261 | P20908 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9014 | P20908 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 26675 | P20908 | Espacenet |
1 to 10 of 98
See all 98 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials66
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06169319 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT06151197 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT06065436 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05646602 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05254457 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT05152173 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT04874870 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT04680156 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT04496167 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2023-09-13 | ClinicalTrials.gov |
| NCT04236635 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2022-04-12 | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsNIH grants1,704
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | COL5A1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 9 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 9 | 2025 |
| P20GM103408 | Idaho INBRE Program | 5 | 2025 |
| P30AR069619 | Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application) | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 5 | 2025 |
| P30EY014104 | P30 Core Grant for Vision Research | 5 | 2025 |
| UL1TR001881 | UCLA Clinical and Translational Science Institute | 5 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 4 | 2025 |
| R01EY022305 | NEIGHBORHOOD Consortium for POAG Genetics | 4 | 2025 |
1 to 10 of 1,704Source NIH's project files
See all 1,704 nih grantsPapers3,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Variability of Classical Ehlers-Danlos Syndrome: A Family with Rare COL5A1 Variant and Case-Based Review. | Int J Mol Sci | 2026 | 42737849 | PubTator, text mining | PubMed |
| Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma. | Int J Biol Sci | 2026 | 42694774 | PubTator, text mining | PubMed |
| Integrated Analysis of Multiple Databases Identifies Tissue Inhibitor of Metalloproteinase 1 Expression and Its Association with the Immune Microenvironment in Colorectal Cancer. | Genes (Basel) | 2026 | 42650169 | PubTator, text mining | PubMed |
An Integrative Bioinformatics Framework Nominates Candidate Limbal Stem-Cell Exosome Cargo for Keratoconus by Coupling Corneal Transcriptomics, Disease-Gene Evidence and Extracellular-Vesicle Repositories. | Bioengineering (Basel) | 2026 | 42649743 | PubTator, text mining | PubMed |
| Prognostic and immunological value of LINC01615-related genes in kidney clear cell carcinoma: Integrated bioinformatics analysis and expression validation. | Medicine (Baltimore) | 2026 | 42629666 | PubTator, text mining | PubMed |
| Identification of Glycolysis-Related Diagnostic Biomarkers for Amyotrophic Lateral Sclerosis Using Machine Learning. | Clin Lab | 2026 | 42570648 | PubTator, text mining | PubMed |
| Multigene panel analysis of connective tissue and vascular genes in patients with a bleeding disorder of unknown cause or a cerebrovascular event. | Res Pract Thromb Haemost | 2026 | 42568836 | PubTator, text mining | PubMed |
| Identification of extracellular matrix-associated signatures to establish a risk model in rheumatoid arthritis and osteoarthritis through transcriptomic analysis. | Transl Res | 2026 | 42556611 | PubTator, text mining | PubMed |
| Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial. | EBioMedicine | 2026 | 42531722 | PubTator, text mining | PubMed |
| Systems Biology and Experimental Validation Enable Discovery of MMP9-Centered Networks, Anticancer Activity, and Pharmacodynamic Signature in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | 42511800 | PubTator, text mining | PubMed |
1 to 10 of 3,043
See all 3,043 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1289
GET https://conductscience.org/api/genes/v1/1289/patents?page=2